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Background: We compared two recently developed re-
search assays for the measurement of human kallikrein
2 (hK2) in serum: one fully automated assay (Beckman
Coulter Access® immunoanalyzer) and one manual as-
say based on the DELFIA® technology.
Methods: We used two subsets of clinical specimens
consisting of 48 samples from prostate cancer patients
and 210 samples from participants in an ongoing screen-
ing study (ERSPC). Both subsets were measured in the
Rotterdam laboratory, and the prostate cancer samples
were used for analytical comparison with the originat-
ing sites for the assays: Beckman Coulter Research
Department (San Diego, CA) and Turku University
(Turku, Finland).
Results: Both the Beckman Coulter and the Turku
assays performed very similarly between the Rotterdam
laboratory and the originating sites: the R2 value for
both comparisons was 0.99, and the slope difference
between sites was <20%. Deming regression analysis of
the DELFIA (y) and Access (x) assays yielded the fol-
lowing: for the prostate cancer group, y  1.17x  0.01
(R2 0.88; n 48); and for the ERSPC group, y 0.62x
0.01 (R2  0.77). Breakdown of the latter group into
subgroups (nondiseased, benign prostatic hyperplasia,
and prostate cancer samples) gave only minor differ-
ences. The Access calibrators were underrecovered by
13% in the DELFIA assay, whereas the DELFIA calibra-
tors were overrecovered by 45% in the Access assay.
Conclusion: The DELFIA and Access assays for hK2,
which have similar analytical features, show differences
that cannot be explained by calibration.
© 2003 American Association for Clinical Chemistry
An important tumor marker in use in clinical oncology is
prostate-specific antigen (PSA).5 Because of its sensitivity
and its organ specificity, this marker is applied in popu-
lation screening and diagnosis and monitoring of patients
with prostate cancer (PCa) (1 ). However, the discrimina-
tory power of total PSA between the prostate disorders
benign prostate hyperplasia (BPH) and PCa is limited (2 ).
To increase both the sensitivity and the specificity of
PSA, many efforts have been made: use of different
molecular forms of PSA (free PSA, complexed PSA, total
PSA), combination of markers with clinical information
(PSA density, PSA velocity, age-specific reference values
for PSA), and more recently, the search for new molecular
markers (3–5). Promising data have appeared in the
literature on the application of human kallikrein 2 (hK2)
as a prostate disease marker (6 ), and several assays for
hK2 have been described. We realized that for hK2 to be
successfully used, current assays would need to be com-
pared and eventually standardized as was done for PSA.
Our three institutions, University Hospital Rotterdam,
the University of Turku, and Hybritech, a subsidiary of
Beckman Coulter Inc. (HBC), have collaborated to start
the standardization process on two assays that have been
the subject of several reports (7–13). The current report
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sent-based side study of the Rotterdam section of the
European Randomized Study of Screening for Prostate
Cancer (ERSPC) (14 ). Samples were stored for up to 4
years at80 °C and were thawed and frozen twice during
this study. All 210 samples came from individuals from
whom we had obtained prostate biopsy results. On the
basis of biopsy results, transrectal ultrasound prostate
volume, and serum PSA, the individuals were divided
into three groups: group 1, healthy individuals (biopsy
negative for cancer; prostate volume 40 mL, total PSA,
1.0–7.0 g/L; n  72); group 2, BPH patients (biopsy
negative for cancer; prostate volume 40 mL; total PSA,
2.8–9.6 g/L; n  60); and group 3, PCa patients (biopsy
positive for cancer; total PSA, 1.4–10.2 g/L; n  78).
An additional panel of 48 less-characterized samples
was obtained from our clinical serum bank (samples also
stored at 80 °C) for offsite vs onsite assay comparisons.
These were nontraceable excess clinical serum samples
from PCa patients with PSA values between 1.1 and 28.8
g/L that were selected at random. For the sake of clarity,
we will use the term “uncharacterized” for these samples.
automated hK2 Access® assay
The automated hK2 assay, developed for research pur-
poses, is an adaptation of the microtiter version described
previously (15 ) to be performed on the Beckman Coulter
Access immunoanalyzer (Beckman Coulter Inc.). The au-
tomated version of the hK2 assay is very similar in assay
performance to the manual microplate version. The min-
imum detectable concentration (MDC) for this assay is
0.008 g/L, and its cross-reactivity to PSA is 0.001%.
The calibrator used in this assay was recombinant mature
hK2 (15 ).
manual DELFIA® hK2 assay
The DELFIA-based assay for hK2 is a modification of a
previously described time-resolved fluorescence method
developed for research (16 ). The whole procedure is
performed manually. Its cross-reactivity to PSA is
0.01%. The calibrator used in this assay is an activated
form of mutated recombinant hK2 (17 ).
mdc, precision, and recognition of hK2 and hK2–
1-antichymotrypsin
The MDC was assessed by assaying 10 replicates of the
zero calibrators and 3 replicates of the lowest non-zero
calibrator. The assays were performed once each on 2
consecutive days (15 ). The between-run precision was
measured with use of one serum pool (hK2 concentration,
0.056 g/L; Access hK2 assay). We analyzed two samples
consisting of free hK2 and hK2 complexed with 1-
antichymotrypsin (ACT), respectively, to directly com-
pare the recognition of both molecular forms. These
samples were, by definition, matched on a molar basis
(15 ). The calibrators for the DELFIA hK2 assay were run
in the Access hK2 assay and vice versa so that the
calibration for the two assays could be compared.
correlation of assays among the three sites
We performed a comparison study to check the correla-
tion of the two hK2 assays being run at University
Hospital Rotterdam laboratory with the originating labo-
ratories for each of the two hK2 assays. For this purpose,
we tested 48 uncharacterized clinical samples in the
Rotterdam laboratory and then shipped aliquots of those
same samples to both HBC (San Diego) for comparison
with the hK2 Access assay and to the Department of
Biotechnology of the University of Turku (Finland) for
comparison with the AutoDELFIA® hK2 assay. In both
cases the chemistries were identical and the reagent lots
were the same between our site and the originating
laboratory.
comparison of the two assays on patient
samples
Both hK2 assays in Rotterdam were used to assay the
uncharacterized and the characterized panels.
statistics
All statistical calculations, including Deming regression
analysis, were performed with the statistical program
Analyze-It (Analyze-It Software Ltd.).
Results
In Rotterdam, the imprecision (as CV) at a hK2 concen-
tration of 0.056 g/L was: for the Access, a CV of 3.0%
over 6 days; and for the DELFIA, a CV of 8.9% over 11
days. The lower limits of detection were 0.008 g/L for
the Access assay and 0.007 g/L for the DELFIA assay.
The activities of both assays toward free and uncom-
plexed hK2 were compared directly by measuring
matched calibrators for these analytes at Rotterdam and at
their original sites. The hK2/hK2-ACT ratio was similar
for both assays, with the DELFIA assay being slightly
more equimolar than the Access assay: DELFIA, 1.15 and
1.10; Access, 1.28 and 1.29.
The calibrators for the DELFIA assay were measured
with the Access assay and vice versa to compare calibra-
tor recovery between the two assays. Regression analysis
yielded the following equations: for the Access calibra-
tors, y (Rotterdam, DELFIA)  0.79x  0.01 g/L and y
(Turku, DELFIA) 0.95x; and for the DELFIA calibrators,
y (Rotterdam, Access)  1.31x  0.01 g/L and y (San
Diego, Access)  1.59x  0.01 g/L.
Both the Turku and the HBC assays performed very
similarly between the Rotterdam site and their respective
originating sites (Fig. 1A and B). The regression line for
Fig. 1A is: y  0.82x  0.02 g/L (R2  0.99), and that for
Fig. 1B is: y  0.87x  0.01 g/L (R2  0.99).
Once the assays were compared site to site, the char-
acterized set of 210 samples from the ERSPC was tested in
both assays in Rotterdam (Fig. 1C). We found the follow-
ing equation for the regression line: y 0.62x 0.01 g/L
(R2  0.77). The slopes and R2 values for the three
subgroups differed only slightly from the values obtained
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for the entire group (data not given). Fig. 1D is a graph
comparing the results obtained for the uncharacterized
specimens as measured in the Rotterdam laboratory using
the same scale as in Fig. 1C. The equation for the regres-
sion line is: y 0.87x 0.03 0.01 g/L (R2 0.64; n 40).
Table 1 contains statistical information on both markers,
hK2 and PSA, for both sample sets.
Finally, when we applied the Bland–Altman procedure
Fig. 1. Comparisons of the hK2 assay between different laboratories.
(A and B), comparison of the Access assay between San Diego and Rotterdam (A) and the DELFIA assay between Turku and Rotterdam (B), both with clinical samples.
(C and D), comparison of the DELFIA and Access assays using ERSPC samples (C) and clinical samples (limited range; D). The regression equations for the lines are
given in the text.





Total 210 3.9 (1.0–10.2) 0.06 (0.01–0.41) 0.13 (0.02–0.51)
Healthy individuals 72 1.9 (1.0–7.0) 0.04 (0.01–0.20) 0.08 (0.02–0.38)
BPH 60 4.7 (2.8–9.6) 0.10 (0.01–0.41) 0.17 (0.02–0.51)
PCa 78 4.4 (1.4–10.2) 0.08 (0.01–0.23) 0.15 (0.03–0.38)
Clinical samples
PCa 48 12.1 (1.1–28.8) 0.15 (0.00–2.91) 0.14 (0.00–2.23)
aResults are given as the median (range).
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(differential plots) and calculated the standard error of the
mean difference, we found no evidence for systematic
bias for the comparisons shown in panels A and D of Fig.
1 vs those shown in panels B and C.
Discussion
It has been shown that the hK2 concentration in serum
corresponds to 1–2% of the total PSA concentration
(6, 11, 15). The exact physiologic role of hK2 in relation to
the biochemistry of PSA is not sufficiently known, al-
though several aspects have been described (11 ). From
the recent reports on hK2 in the literature, it appears that
hK2 concentrations in serum may be increased in malig-
nant prostate disease. Preliminary data show that hK2
measurements may aid in the detection of PCa (7 ) or may
help predict the stage and grade of PCa (9–11, 13). These
data indicate that hK2 may have value as a pretreatment
marker in PCa evaluation.
To date, no commercial hK2 assays are available. The
assays we have compared are (modifications of) the
assays that were used in the majority of the clinical
publications. To our knowledge, this is the first report of
an analytical comparison study on hK2 assays. It is
therefore difficult to compare the current clinical litera-
ture for the usefulness of hK2 without knowing how the
assays compare directly in the laboratory. The results
shown in Fig. 1 indicate that the performance of the two
assays in the Rotterdam laboratory was very similar to
their performance in the originating laboratories. There-
fore, the comparison of the assays at the Rotterdam site is
indicative of and confirms the reliability of the data
produced by these assays in the previous clinical studies.
We next compared the assay data from both the
characterized (ERSPC) samples and the uncharacterized
samples. The slope of the correlation curve between the
two assays for all 210 of the ERSPC samples indicated that
in the Access hK2 assay, on average, recovery of hK2 was
38% higher than in the DELFIA assay. There was
considerable scatter between the assays.
Differences in calibration can explain part of slope
differences between the assays. We noticed that the Ac-
cess calibrators were underrecovered by 13% (averaged
values of both Access sites) in the DELFIA assay, whereas
the DELFIA calibrators were overrecovered by 45% (av-
eraged values of both DELFIA sites) in the Access assay.
However, we emphasize that calibration cannot be the
only source of the assay differences because in addition to
the differences in calibrator recovery, there was substan-
tial scatter in the correlation curves (Fig. 1C).
There are several possibilities for these additional
differences between the assays. Simple analyte stability
should not be an issue in this comparison because the
same samples were mostly run under the same conditions
on the same day. If degradation (e.g., proteolytic degra-
dation of the serum hK2, which would completely elimi-
nate the signal in both assays) had occurred, it should
have occurred equivalently in all samples. Nevertheless, a
more complex type of degradation (e.g., partial proteo-
lytic degradation of specific epitopes within the serum
hK2) that would partially eliminate the signal in one assay
but not the other may be possible. The Access assay
recovers less hK2 signal in samples containing hK2 that
has been proteolytically degraded (15 ). In addition, we
have observed that the DELFIA assay does not recognize
degraded forms of hK2 (unpublished results). Nothing is
known about the reaction pattern of possible glycosylated
hK2 forms.
PSA assays have actually exploited differences in pro-
teolysis of the antigen to aid in discriminating benign
disease from PCa (18, 19). Therefore, differences in pro-
teolytically degraded hK2 forms could also explain some
of the differences found between the different clinical
groups (20 ).
Some of the differences between the correlations in the
different groups (Table 1) might be attributable to the hK2
range that is being measured. The hK2 concentration
range in samples from healthy individuals is obviously
different from that in the cancer samples. This difference
is even clearer if we consider the uncharacterized sample
group, which consisted of only cancer specimens. We
found several high hK2 values in this group. However,
the sample concentration range does not completely ex-
plain the observed differences (Fig. 1).
Another possibility for differences between the two
assays could be their ability to measure complexed vs free
forms of hK2. The assays showed very similar ratios of
reactivity on hK2 vs hK2-ACT, so it is unlikely those
differences in hK2/hK2-ACT ratios in the patient samples
would contribute much to the difference between assay
values. Furthermore, it has already been shown that the
vast majority of hK2 in serum appears to be free (16, 21).
Recognition of complexed forms of hK2 may be not be as
important for hK2 as it is for PSA.
In conclusion, we have shown that the Access and
DELFIA for hK2 actually are quite different. Even if both
assays are calibrated with the same hK2 standard, we
predict that there will still be some differences in patient
correlations between these two assays. Nevertheless, use
of a common calibrator for both assays could eliminate
one significant cause of error, and other factors influenc-
ing the result could then be identified more easily. This
should eliminate much confusion and should be much
easier to implement at this point in the clinical use of hK2
than it was to standardize PSA (22, 23) because PSA was
already being used routinely in clinical laboratories.
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